EMEA To Get To Heart Of COX-2 Inhibitor Safety Issues At Feb. 14-17 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The Committee for Medicinal Products for Human Use requests further analyses from Pfizer, Merck and Novartis on the cardiovascular safety of COX-2 inhibitors. Pfizer agrees not to launch celecoxib for in an orphan polyp indication until after completion of EMEA's class safety review.